SB-480848 In Subjects With Coronary Heart Disease

Inclusion criteria: * Female subjects must be of non-childbearing potential. * Stable CHD or CHD-risk equivalent. * Must have been on a stable dose of a statin for =4 weeks with LDL \<130 mg/dL (3.4 mmol/L) or off statin therapy for =4 weeks with LDL \<160 mg/dL (4.1 mmol/L). * On a stable dose of at least one oral antiplatelet agent (e.g., aspirin, clopidogrel, or ticlopidine). Exclusion criteria: * Recent cardiovascular event and / or vascular procedure. * History of difficult to manage dyslipidemia. * Planned cardiac surgery or PCI (percutaneous coronary intervention) or planned major non-cardiac surgery. * Inadequately controlled hypertension. * Poorly controlled diabetes mellitus. * Serum triglycerides \>400 mg/dL (4.52 mmol/L). * Recent or ongoing acute infection. * History of chronic inflammatory disease. * Receiving topical, oral, inhaled or injectable corticosteroids. * History of chronic viral hepatitis, or other chronic hepatic disorders. * History of kidney transplant. * History of myopathy or inflammatory muscle disease, or elevated total serum CK (3 x ULN). * Severe heart failure (NYHA class III or IV), or severe left ventricular dysfunction (ejection fraction \<30%). * Asthma manifested by bronchospasm in the past 6 months, or currently taking inhaled bronchodilator on regular basis. * History of anaphylaxis, anaphylactoid reactions or severe allergic responses within the past 6 months. * Malignancy within the past 2 years, other than non-melanoma skin cancer. * Current life-threatening condition other than vascular disease that may prevent a subject from completing the study. * QTc interval \>440 msec (males) or \>450 msec (females). * Alcohol or drug abuse within the past 6 months. * Previous exposure to SB-480848. * Use of an investigational drug within 30 days or 5 half-lives (whichever is the longer) preceding the first dose of study medication (blinded atorvastatin).